Novartis, the world’s sixth largest drugs group, reported consensus beating sales and profits in the third quarter on the back of acquisitions and lower than expected one-off costs.

The Swiss pharmaceuticals group said on Tuesday that net profits rose by 13 per cent to $1.67bn, while sales increased by 19 per cent to $8.42bn.